Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health Canada Advisory Panel Recommends Increased Accutane Physician Education

This article was originally published in The Pink Sheet Daily

Executive Summary

Committee unanimously rejects patient registry system that would be similar to U.S. iPLEDGE risk management program.

You may also be interested in...

FDA Approves "Unprecedented" Risk Management Program For Accutane

Wholesalers, pharmacists, prescribers and patients will have added responsibility under the iPLEDGE program.

Isotretinoin Psychiatric Disorder Warning Strengthened

Revised labeling for isotretinoin (Roche's Accutane and generics) suggests prescribers ask patients about psychiatric disorders prior to treatment initiation and continue that discourse throughout treatment

Italy Leads European Push Into Conditional Reimbursement

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts